Literature DB >> 15686962

Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport.

Olivia Hurtado1, María A Moro, Antonio Cárdenas, Verónica Sánchez, Paz Fernández-Tomé, Juan C Leza, Pedro Lorenzo, Julio J Secades, Rafael Lozano, Antoni Dávalos, José Castillo, Ignacio Lizasoain.   

Abstract

BACKGROUND AND
PURPOSE: Cytidine-5'-diphosphocholine (citicoline or CDP-choline), an intermediate in the biosynthesis of phosphatidylcholine, has shown beneficial effects in a number of CNS injury models including cerebral ischemia. Citicoline is the only neuroprotectant that has proved efficacy in patients with moderate to severe stroke. However, the precise mechanism by which citicoline is neuroprotective is not fully known. The present study was designed to search for mechanisms of citicoline neuroprotective properties using in vivo and in vitro models of brain ischemia.
METHODS: Focal brain ischemia was produced in male adult Fischer rats by occluding both the common carotid and middle cerebral arteries. Brain glutamate levels were determined at fixed intervals after occlusion. Animals were then sacrificed, and infarct volume and brain ATP levels were measured. As in vitro model of ischemia, rat cultured cortical neurones or astrocytes, isolated or in co-culture, were exposed to oxygen-glucose deprivation (OGD) either in the absence or in the presence of citicoline (1-100 microM). Viability was studied by measuring LDH release. Glutamate release and uptake, and ATP levels were also determined.
RESULTS: Citicoline (0.5, 1 and 2 g/kg i.p. administered 1 h before the occlusion) produced a reduction of the infarct size measured at striatum (18, 27 and 42% inhibition, respectively, n = 8, P < 0.05 vs. ischemia), effect that correlated with the inhibition caused by citicoline on ischemia-induced increase in glutamate concentrations after the onset of the ischemia. Citicoline also inhibited ischemia-induced decrease in cortical and striatal ATP levels. Incubation of cultured rat cortical neurones with citicoline (10 and 100 microM) prevented OGD-induced LDH and glutamate release and caused a recovery in ATP levels after OGD, confirming our previous results. In addition, citicoline (100 microM) caused an increase in glutamate uptake and in EAAT2 glutamate transporter membrane expression in cultured rat astrocytes.
CONCLUSIONS: Our present findings show novel mechanisms for the neuroprotective effects of citicoline, which cooperate to decrease brain glutamate release after ischemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15686962     DOI: 10.1016/j.nbd.2004.10.006

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  26 in total

Review 1.  Possible Benefit and Validity of Supplements for Alcohol Use Disorder.

Authors:  Seungwoo Kang; Doo-Sup Choi
Journal:  Alcohol Clin Exp Res       Date:  2019-03-14       Impact factor: 3.455

2.  CDP-choline liposomes provide significant reduction in infarction over free CDP-choline in stroke.

Authors:  Rao Muralikrishna Adibhatla; J F Hatcher; K Tureyen
Journal:  Brain Res       Date:  2005-10-05       Impact factor: 3.252

Review 3.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

Review 4.  Citicoline in addictive disorders: a review of the literature.

Authors:  Nicholas D Wignall; E Sherwood Brown
Journal:  Am J Drug Alcohol Abuse       Date:  2014-06-20       Impact factor: 3.829

5.  Oct-2 transcription factor binding activity and expression up-regulation in rat cerebral ischaemia is associated with a diminution of neuronal damage in vitro.

Authors:  Susanna Camós; Carme Gubern; Mónica Sobrado; Rocío Rodríguez; Víctor G Romera; María Ángeles Moro; Ignacio Lizasoain; Joaquín Serena; Judith Mallolas; Mar Castellanos
Journal:  Neuromolecular Med       Date:  2013-11-27       Impact factor: 3.843

Review 6.  Cytidine 5'-diphosphocholine (CDP-choline) in stroke and other CNS disorders.

Authors:  Rao Muralikrishna Adibhatla; J F Hatcher
Journal:  Neurochem Res       Date:  2005-01       Impact factor: 3.996

7.  A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline in Patients with Alcohol Use Disorder.

Authors:  E Sherwood Brown; Erin Van Enkevort; Alexandra Kulikova; Chastity Escalante; Alyson Nakamura; Elena I Ivleva; Traci Holmes
Journal:  Alcohol Clin Exp Res       Date:  2018-12-24       Impact factor: 3.455

8.  Citicoline protects against cognitive impairment in a rat model of chronic cerebral hypoperfusion.

Authors:  Hyun Joon Lee; Ji Seung Kang; Yeong In Kim
Journal:  J Clin Neurol       Date:  2008-03-31       Impact factor: 3.077

9.  Validation of housekeeping genes for quantitative real-time PCR in in-vivo and in-vitro models of cerebral ischaemia.

Authors:  Carme Gubern; Olivia Hurtado; Rocío Rodríguez; Jesús R Morales; Víctor G Romera; María A Moro; Ignacio Lizasoain; Joaquín Serena; Judith Mallolas
Journal:  BMC Mol Biol       Date:  2009-06-16       Impact factor: 2.946

10.  Cytidine-5-diphosphocholine supplement in early life induces stable increase in dendritic complexity of neurons in the somatosensory cortex of adult rats.

Authors:  V Rema; K K Bali; R Ramachandra; M Chugh; Z Darokhan; R Chaudhary
Journal:  Neuroscience       Date:  2008-04-16       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.